Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446490 | 0.90 | ABL1 (0.49) | ABL1BCRKCNH2MAP4K4PIK3CA | |
| SCHEMBL16906526 | 0.83 | ABL1 (0.46) | ABL1BCRKCNH2MAP4K4PIK3CA | |
| SCHEMBL10220818 | 0.83 | MAPT (0.38) | — | |
| SCHEMBL16903662 | 0.81 | ABL1 (0.48) | ABL1BCR | |
| SCHEMBL28155918 | 0.79 | ABL1 (0.46) | ABL1BCRKCNH2MAP4K4PIK3CA | |
| SCHEMBL16894253 | 0.79 | ABL1 (0.46) | ABL1BCRKCNH2MAP4K4PIK3CA | |
| SCHEMBL16903677 | 0.79 | TRPA1 (0.44) | ABL1BCRKCNH2MAP4K4PIK3CA | |
| SCHEMBL28017373 | 0.79 | ABL1 (0.55) | ABL1BCRKCNH2MAP4K4PIK3CA | |
| Hydrochloric Acid SCHEMBL28017385 | 0.78 | ABL1 (0.54) | ABL1BCRKCNH2MAP4K4PIK3CA | |
| SCHEMBL10219992 | 0.77 | MKNK1 (0.43) | KCNH2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580411-B2 | Substituted sulfonamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | GENENTECH, INC. (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197509-A1 | SUBSTITUTED SULFONAMIDE SOLUTIONS | TRPA1, TRPV1, TRPV5 | ABL1 1402/4885BCR 1371/4885KCNH2 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.